Mangoceuticals, Inc. (NASDAQ:MGRX) Short Interest Update

Mangoceuticals, Inc. (NASDAQ:MGRX) was the target of a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 1,882,096 shares, a growth of 805.4% from the July 15th total of 207,868 shares. Based on an average trading volume of 49,406,730 shares, the days-to-cover ratio is currently 0.0 days. Approximately 13.1% of the shares of the stock are short sold.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MGRX. Ikarian Capital LLC acquired a new position in Mangoceuticals in the 4th quarter worth about $102,000. Virtu Financial LLC purchased a new stake in shares of Mangoceuticals during the 4th quarter worth about $25,000. Boothbay Fund Management LLC acquired a new stake in shares of Mangoceuticals during the 4th quarter valued at about $28,000. Jane Street Group LLC acquired a new stake in shares of Mangoceuticals during the 4th quarter valued at about $35,000. Finally, Geode Capital Management LLC grew its stake in shares of Mangoceuticals by 35.4% in the 2nd quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock valued at $40,000 after buying an additional 6,928 shares in the last quarter. 56.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on MGRX shares. Wall Street Zen raised Mangoceuticals to a “sell” rating in a report on Saturday, July 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Mangoceuticals in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Mangoceuticals Price Performance

NASDAQ MGRX traded down $0.05 on Tuesday, hitting $0.55. 1,344,309 shares of the company were exchanged, compared to its average volume of 37,237,344. The company’s 50 day moving average price is $0.42 and its 200-day moving average price is $0.41. The firm has a market capitalization of $9.37 million, a P/E ratio of -0.37 and a beta of 2.10. Mangoceuticals has a twelve month low of $0.16 and a twelve month high of $2.75.

Mangoceuticals (NASDAQ:MGRX) last posted its quarterly earnings data on Tuesday, May 19th. The company reported ($0.22) EPS for the quarter. Mangoceuticals had a negative return on equity of 112.00% and a negative net margin of 4,639.13%.The firm had revenue of $0.07 million during the quarter.

About Mangoceuticals

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.